Immune control of tuberculosis by IFN-gamma-inducible LRG-47

IFN-γ 诱导型 LRG-47 对结核病的免疫控制

基本信息

  • 批准号:
    7470658
  • 负责人:
  • 金额:
    $ 31.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Natural mutations in humans and introduced mutations in mice have unequivocally demonstrated the importance of interferon-gamma (IFN-gamma) for the control of tuberculosis (TB). How this cytokine exerts its protective effects is thought to owe much to the broad transcriptional programs it activates within Mycobacterium tuberculosis (Mto)-infected macrophages and dendritic cells. Here as many as 1,300 genes may be engaged. Prominent within this group is a new family of 47kDa guanosine 5'-triphosphatases (p47 GTPases) that confers host resistance to a number of human pathogens. At least one member of this family - LRG-47 - appears essential for combating TB in experimental mouse models. Preliminary evidence suggests that LRG-47 operates at the level of the infected cell via a mechanism distinct from all known tuberculocidal pathways, linking cytokine activation with phagolysomal fusion, events that are required for bacterial killing and which may enable Mtb antigens to be cross-presented. It is the purpose of this proposal to build on these initial observations by pursuing the following aims: (1) Characterize the intracellular location and trafficking behavior of mouse and human LRG-47 within Mtb-infected cells. Here a combination of high-resolution imaging and cell fractionation will be used to identify the LRG-47-positive compartment(s) and its recruitment to the nascent Mtb phagosome. (2) Define the molecular determinants of LRG-47 function in response to Mtb. Relocation of LRG-47 to the Mtb phagosome and subsequent remodeling of this organelle is likely to enlist other host proteins. Isolating LRG-47-interacting partners, the functional domains involved and their consequences for immunity will be dissected with an array of molecular, cellular and structural approaches. (3) Uncover Mtb-encoded pathways that counter LRG-47 - dependent immunity. Genetic screens conducted to identify bacterial components interfering with LRG-47 should yield further insights into how this GTPase operates. It could also uncover prospective drug targets. Information gleaned from these approaches will provide a paradigm for other members of the p47 GTPase family that is rapidly emerging as one of the most powerful host defense repertoires in the mammalian genome.
描述(由申请方提供):人类中的自然突变和小鼠中的引入突变已明确证明干扰素-γ(IFN-γ)对控制结核病(TB)的重要性。这种细胞因子如何发挥其保护作用被认为是由于它在结核分枝杆菌(Mto)感染的巨噬细胞和树突状细胞内激活了广泛的转录程序。这里可能有多达1,300个基因参与其中。在该组中突出的是47 kDa鸟苷5 '-三磷酸酶(p47 GTP酶)的新家族,其赋予宿主对许多人类病原体的抗性。这个家族中至少有一个成员-- LRG-47 --在实验小鼠模型中似乎对抗击结核病至关重要。初步证据表明,LRG-47通过与所有已知的杀结核途径不同的机制在感染细胞水平上起作用,将细胞因子活化与吞噬溶酶体融合联系起来,这是细菌杀伤所需的事件,可能使Mtb抗原交叉呈递。本提案的目的是通过追求以下目标来建立这些初步观察结果:(1)表征小鼠和人LRG-47在Mtb感染细胞内的细胞内定位和运输行为。在此,将使用高分辨率成像和细胞分级分离的组合来鉴定LRG-47阳性隔室及其向新生Mtb吞噬体的募集。(2)定义LRG-47响应结核分枝杆菌功能的分子决定因素。LRG-47的迁移到结核分枝杆菌吞噬体和随后的重塑这个细胞器可能会招募其他宿主蛋白质。分离LRG-47相互作用的合作伙伴,所涉及的功能结构域及其对免疫的后果将与一系列的分子,细胞和结构的方法进行解剖。(3)发现Mtb编码的途径,对抗LRG-47依赖性免疫。进行遗传筛选,以确定干扰LRG-47的细菌成分,应该产生进一步的见解,这种GTdR如何运作。它还可以发现潜在的药物靶点。从这些方法中收集的信息将为p47 GTdR家族的其他成员提供一个范例,该家族正迅速成为哺乳动物基因组中最强大的宿主防御系统之一。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John David MacMicking其他文献

John David MacMicking的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John David MacMicking', 18)}}的其他基金

GBPs as new inflammsome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症调节剂
  • 批准号:
    8929155
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammsome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症调节剂
  • 批准号:
    9124701
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammsome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症调节剂
  • 批准号:
    8816302
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammasome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症小体调节剂
  • 批准号:
    10535452
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammasome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症小体调节剂
  • 批准号:
    10307127
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammasome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症小体调节剂
  • 批准号:
    10083168
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
GBPs as new inflammsome regulators during mammalian host defense
GBP 作为哺乳动物宿主防御过程中新的炎症调节剂
  • 批准号:
    9330052
  • 财政年份:
    2014
  • 资助金额:
    $ 31.53万
  • 项目类别:
A Novel CDN Sensor-Adaptor System for Host Defense Against Infection
用于主机防御感染的新型 CDN 传感器适配器系统
  • 批准号:
    10165463
  • 财政年份:
    2006
  • 资助金额:
    $ 31.53万
  • 项目类别:
Immune control of tuberculosis by IFN-gamma-inducible LRG-47
IFN-γ 诱导型 LRG-47 对结核病的免疫控制
  • 批准号:
    7250105
  • 财政年份:
    2006
  • 资助金额:
    $ 31.53万
  • 项目类别:
Immune control of tuberculosis by IFN-gamma-inducible LRG-47
IFN-γ 诱导型 LRG-47 对结核病的免疫控制
  • 批准号:
    7644539
  • 财政年份:
    2006
  • 资助金额:
    $ 31.53万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 31.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了